Beijing Authorities Find Positive Covid-19 Cases At Daimler Shunyi Plant

JAKARTA - The Shunyi District Authority, China found the corona virus from samples taken at the automotive manufacturer Daimler Northeast Asia Parts Trading and Services.co, after previously finding a positive case of COVID-19 in Shunyi District.

Shunyi District Senior Official, Zhi Xianwei in his remarks as reported by local media, Monday, January 4, revealed that the discovery of a positive case of Covid-19 from the Vehicle Parts Sales Division of a German manufacturer located in Jinma Industrial Zone, Shunyi District on December 26, 2020 then.

Zhi said, his party immediately carried out control, by prohibiting people, vehicles and goods from leaving or entering the area. This includes the suspension of all food companies in the industrial area not far from Beijing Capital Airport (BCIA).

"Of the 8,615 people in the industrial area who underwent a swab test, 11 people from Daimler and one from BIT Hua Chuang Electric Vehicle Technology Co were positive (COVID-19)," explained Zhi.

As a result of the discovery of this new case, a number of cities in China are investigating all merchandise sent from several companies in Beijing, in order to prevent the transmission of COVID-19. Such as Hohhot (Inner Mongolia), Cangzhou (Hebei), Yantai and Linyi (Shandong) and Jinchen (Shanxi).

Separately, the Beijing Municipal Health Commission revealed that his party had started giving COVID-19 vaccinations to residents since Friday, January 1. It was recorded that 73,537 residents had received vaccinations that were held in 220 places.

Beijing Municipal Health Commission spokesman Gao Xiaojun said that so far there were no serious side effects felt by the vaccine recipients, which are prioritized for nine high-risk groups aged 18-59 years.

"Nine groups are categorized as high risk, including customs inspectors for imported frozen goods, Chinese workers or students who want to travel abroad, and transportation sector workers," explained Gao.

For your information, the National Medical Products Agency has given Sinopharm a limited approval for marketing of China's domestic vaccines as of December 31, 2020.